Abstract: An electronic device may include a stereoscopic display that is configured to display three-dimensional content for a viewer. The stereoscopic display may include a lenticular lens film with lenticular lenses that extend across the length of the display and may be referred to as a lenticular display. The lenticular display may have convex curvature. The lenticular display may include a color filter layer with color filters and an opaque masking layer. The color filter layer may be interposed between the lenticular lens film and an array of display pixels for the display. The color filter layer may mitigate ghost image artifacts and reflections of ambient light. Microlenses may be included between the lenticular lens film and the array of display pixels to improve the efficiency of the display. The display may include a Fresnel lens layer. The lenticular lens film may include lenticular lenses having different shapes.

Abstract: An aqueous formulation includes a PEDF-derived short peptide (PDSP) having the sequence of one of SEQ ID NO: 1, 2, 3, 5, 6, 8 or 9; boric acid at a concentration of 0.01 mM-923 mM; and a non-ionic tonicity agent. The pH value is around 5.5-8.4. The non-ionic tonicity agent is glycerin, sucrose, mannitol, or sorbitol. A concentration of the PDSP is 0.01%-1% w/v.

Abstract: Monoclonal antibodies against human Mac-1 are provided. These antibodies can bind to different states of Mac-1 so as to alter the biofunctions of Mac-1. These antibodies can modulate Th1/Th2 cytokine secretions by TLR-activated immune cells and can be used for the treatments of diseases related to acute and chronic inflammatory disorders, such as infectious diseases, and cancers.

Abstract: An aqueous formulation includes a PEDF-derived short peptide (PDSP) having the sequence of one of SEQ ID NO: 1, 2, 3, 5, 6, 8, or 9; histidine having a concentration of 1 mM-100 mM; and an antioxidant and optionally a non-ionic tonicity agent. The pH value is around 5-9. The antioxidant is nicotinamide, which is at a concentration of 50 mM-1000 mM. The non-ionic tonicity agent is sorbitol, which is at a concentration of 0 mM-500 mM. A concentration of the PDSP is 0.01%-1% w/v.

Abstract: A pharmaceutical composition for boosting an immune response contains TREM-like transcript-1 (TREML1) extracellular domain (ECD) or stalk polypeptide. The TREML1 ECD or stalk polypeptide is derived from human or mouse TREML1. The pharmaceutical composition further contains an antigen as a vaccine, wherein the TREML1 ECD or stalk polypeptide functions as an adjuvant or immune booster.

Abstract: A hepatitis B virus (HBV) vaccine includes an HBV core antigen (HBcAg) and/or HBV surface antigen (HBsAg) formulated in nanocomplexes. The nanocomplexes contain chitosan and ?-PGA. These nanocomplexes containing HBc/sAg, chitosan, and ?-PGA can induce more balanced T helper cells (Th1 and Th2) polarization than can a conventional vaccine with an alum adjuvant. HBc/s-NC of the invention can elicit high levels of antibodies against HBsAg, a rapid elimination of HBsAg, and a slow decrease of HBeAg, indicating a phenomenon of HBsAg seroconversion. Thus, HBc/s-NC can overcome immune tolerance caused by chronic HBV infection to re-establish host immunity leading a functional cure.

Abstract: A pharmaceutical composition for use in treating hepatitis B virus (HBV) infection includes an effective amount of an antibody against CD11b or a binding fragment thereof. A method for treating hepatitis B virus infection includes administering to a subject in need thereof an antibody against CD11b. Anti-CD11b antibody binding to CD11b may trigger immunostimulatory responses, as evidenced by the following observations: increased surface expression of MHC II and CD86 in CD11b+ peripheral blood mononuclear cells (PBMCs); suppressed level of hepatitis B surface antigen (HBsAg) and HBV DNA in the blood; and accelerated clearance of HBV from liver.

Abstract: The present invention relates to methods for modulating immune response based on binding I-domain of CD11b on the tumor associated myeloid cells (TAMCs) in the tumor microenvironment. Particularly, binding to I-domain of CD11b with anti-CD11b-I-domain antibody triggers immunostimulatory environment that have one or more of the following effects in the tumor microenvironment: increase the inflammatory cytokine in the tumor microenvironment, decrease the population of IDO+ myeloid suppresser cells, up-regulate M1 marker over M2 marker on the tumor associated macrophage, increase M1:M2 tumor associated macrophage ratio, promote differentiation of dendritic cells (DC), nature killer dendritic cells (NKDC), and plasmacytoid dendritic cells (pDC), increase population of 4?1BB+PD?1+ neoantigen specific CD8 T cells. Converting cold (non-inflamed) to hot (inflamed) tumor by binding to I-domain of CD11b with anti-CD11b-I-domain antibody allows enhanced effectiveness of immune response modulator.

Abstract: A liquid isotope delivery system includes a pressure-controlling unit, an input unit, a target chamber, a proton-radiating unit and a storage unit. The pressure-controlling unit includes a first regulating valve, a second regulating valve connected to the first regulating valve and a third regulating valve connected to the first regulating valve. The input unit is connected to the second regulating valve. The target chamber is connected to the third regulating valve and the input unit. The proton-radiating unit is located near the target chamber. The storage unit is connected to the target chamber.

Abstract: A liquid and a gas is constantly filled into a target chamber of a target. Then the liquid and the gas flow around the chamber and are flown out. By doing so, the target is effectively cooled down.

Abstract: A liquid and a gas is constantly filled into a target chamber of a target. Then the liquid and the gas flow around the chamber and are flown out. By doing so, the target is effectively cooled down.